By Arnaud Bauer, Partner & Pradnyesha Rode, Principal, L.E.K. Consulting
The pattern is now hard to miss. Over the past two years international specialist providers have pushed into the Gulf in oncology, dental and cosmetic dentistry, mental health and fertility, and reports that a large Indian ophthalmology chain is reviewing expansion into the region fit that trend rather than break it. The usual explanation is demand. But demand has been real for a decade. What has changed is that Saudi Arabia is deliberately moving clinical activity into private hands, and is doing so in the formats international specialists are best equipped to deliver. Whether those entrants build durable businesses will depend less on the demand case than on three questions that sit downstream of it: how care is priced, who funds it, and how an operator reaches the patients currently treated in the public system.
What is actually driving the market?
Activity is being moved, not merely permitted. Vision 2030 targets a shift in private sector participation in healthcare from roughly 40% today to 65% by 2030. The Ministry of Health is transitioning from provider to regulator, with public facilities consolidated into regional clusters under the Health Holding Company and moving progressively towards more autonomous, accountable-care style entities. A privatisation pipeline has been announced across nine priority service areas, spanning primary care, diagnostics, extended and long-term care, home care and rehabilitation. In parallel, mandatory insurance for expatriates and much of the privately employed Saudi workforce has created a funded private demand pool that did not exist at scale fifteen years ago. For a specialist operator, the significance is directional certainty: volume is being pushed towards the private sector as a matter of policy.
Care is also leaving the hospital. The fastest-moving part of the market is not the tertiary hospital but the single-specialty and ambulatory formats around it: day surgery, dialysis, ophthalmology, outpatient oncology, diagnostics, rehabilitation and home care. Three forces are behind this. Clinically, procedures that once required an inpatient stay are now routinely delivered as day cases. Economically, they carry a lower fixed cost base, ramp faster and are more capital efficient per unit of activity. And payors, here as elsewhere, prefer the lower-cost setting for the same clinical outcome. There is a capacity argument too: acute beds occupied by patients who belong in post-acute or long-term settings constrain throughput, so building downstream capacity releases upstream capacity.
This matters because the ambulatory format is the one that travels. A standardised single-specialty clinic, with defined protocols, a fixed equipment set and a predictable staffing ratio, can be replicated across borders. A tertiary hospital, whose value sits in a particular medical staff and a particular referral network, rarely can.
Foreign clinical capability is genuinely welcome, which is less common than it sounds. The Kingdom has been actively open to international operators, brands and care models, and has used management contracts, operating partnerships and structured knowledge transfer to bring them in. That openness is not unconditional. Saudisation targets and clinical training obligations are part of the arrangement, and the workforce constraint behind them is real. In our experience, entrants that treat national workforce development and clinical training as part of what they are offering, rather than as a compliance cost to be minimised, move through approvals and partnership discussions materially faster.
Private capacity, however, remains a Tier 1 story. Modern private infrastructure is concentrated in Riyadh, Jeddah and the Eastern Province. Tier 2 and Tier 3 cities are markedly thinner, and in several specialties patients still travel out of region, or out of the Kingdom, for treatment that ought to be available locally. That gap is the largest unserved catchment in the market. It is also the hardest to execute. Insured lives are fewer, self-pay depth is lower, and specialist recruitment and retention are harder, so a full-service standalone site rarely clears an investment hurdle on catchment volume alone. The format most likely to work is hub and spoke: a Tier 1 hub carrying complex and low-frequency work, lighter spokes handling high-volume routine activity, and teleconsultation, centralised reporting and rotating specialist cover holding the network together. That shifts the unit of analysis from the site to the network, which is a different business case from the one most entrants build first.
Three questions decide the outcome
The first is pricing. The Saudi Billing System has standardised coding, but standardised coding is not a tariff. Prices in the private system are set through bilateral negotiation between insurers and providers, with no minimum reimbursement floor, and the payor market is concentrated enough that a new entrant with no volume history has limited leverage. Reimbursement for the same procedure can differ substantially between two providers in the same city. The practical consequence is that revenue forecasts carry unusually wide error bars, which matters most for capital-intensive specialties and for debt financing. Entrants should model the downside on entry-tier rates rather than market averages, and should treat insurer empanelment as a funded workstream with a named owner, because provider set-up and empanelment commonly consume well over a year before meaningful revenue begins.
The second is the funding pathway. Three pools pay for care: government budgets, private insurance and out-of-pocket payment. They behave differently on growth, payment reliability, price sensitivity and service expectation. The most common flaw in entry business cases is a volume forecast built from national or city-level market size without establishing which pool the revenue actually comes from. Get the payor mix wrong and the patient ramp can be exactly right while the yield is not.
The third, and the one most often left until after the investment decision, is access to public patients. Most clinical volume still sits in the public system, so in many specialties the growth question is really an offloading and outsourcing question. Several routes exist: bilateral outsourcing agreements at hospital level, cluster or ministry-led outsourcing, centralised procurement tenders, and concession or public-private partnership structures for new-build capacity. Each carries different economics, risk allocation and institutional sponsor. Seen from outside the system, pathway selection is not always transparent, timelines are difficult to predict, and the absence of a published model-contract library means most transactions are negotiated from first principles. The discipline this demands is simple: decide, before capital is committed, whether the model requires public patient flow or merely benefits from it. If it requires it, secure the contract before building the asset. If it benefits from it, build to private demand and treat public volume as upside rather than as the base case.
Build, partner or acquire
For most international entrants the answer is mostly partner, sometimes build, and rarely acquire. Acquisition is constrained by supply. There are few scaled, independent specialist assets available, and the better ones are held by domestic groups or sovereign-linked platforms and priced accordingly. Where it makes sense, it is usually as a beachhead, buying licences, sites, clinical staff and existing payor contracts, rather than as a way to buy scale.
Partnership is the dominant entry route and, in most cases, the right one. The local partner contributes land, regulatory navigation, payor relationships and access to government counterparties; the international operator contributes the clinical model, the brand and the protocols. The failure mode is familiar: agreements that leave the international partner without real control over clinical standards, staffing and patient experience, which are precisely the assets the market is paying for. Governance terms should be negotiated with that asymmetry in mind.
Building alone is defensible where the model is asset light, standardised and repeatable, and where enough site density can be created in a single catchment to carry a management platform. Ophthalmology, dialysis, diagnostics and day surgery all meet that test. Broad multispecialty hospital development from a standing start, without a local partner or a secured public contract, generally does not.
What separates the entrants who scale
None of this argues against entry. Saudi Arabia’s demand fundamentals are among the strongest in the region and the policy direction is unusually clear. But the discriminator between operators who scale and those who stall at two sites is rarely the quality of the clinical model. It is whether they proved the unit economics of a single site against a specific catchment and a specific payor mix before signing the second lease, and whether they had a defined route to public patient volume before the first. That is unglamorous work. It is also what the next wave of international specialists will be judged on.
About the authors
Arnaud Bauer is a Partner in L.E.K. Consulting’s Healthcare and Life Sciences practice, working across the Gulf Cooperation Council and Southeast Asia. He advises healthcare operators, private investors and government entities on growth strategy, market entry, commercial due diligence and healthcare investment planning, spanning primary to tertiary care, including hospital-based care, specialty outpatient and ambulatory care, and ancillary services. He previously held senior roles at IQVIA in Singapore and at a strategy consulting boutique in Dubai. He holds a Master of Engineering from École Centrale and a Master of Business from ESSEC Business School in partnership with Nanyang Technological University.
Pradnyesha Rode is a Principal in L.E.K. Consulting’s Healthcare and Life Sciences practice in the Gulf Cooperation Council, and has been part of the firm’s healthcare practice since 2018. She leads market assessment, commercial due diligence and growth strategy work for healthcare providers, hospital groups and clinic networks. Her engagements cover feasibility studies for greenfield facilities, clinic network strategies, national capacity and demand planning, and growth and M&A strategies for outpatient specialty providers across the Gulf and Europe. She holds a B.Tech and an MBA, and previously worked at Accenture in the UK.
